120 related articles for article (PubMed ID: 21403462)
21. [Development of an extramedullary plasmacytoma despite disappearing M protein in multiple myeloma by bortezomib treatment].
Koiso H; Tahara K; Osaki Y; Mawatari M; Sekigami T; Yokohama A; Saitoh T; Uchiumi H; Handa H; Tsukamoto N; Karasawa M; Nojima Y; Murakami H
Rinsho Ketsueki; 2009 Feb; 50(2):78-82. PubMed ID: 19265298
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
Nozza A; Siracusano L; Armando S
Clin Ther; 2006 Jun; 28(6):953-9. PubMed ID: 16860177
[TBL] [Abstract][Full Text] [Related]
23. [Secondary myeloid/natural killer cell acute leukemia appeared in multiple myeloma treated with melphalan].
Kaya H; Nakamura S; Yamazaki H; Kumabashiri I; Ohtake S; Matsuda T
Rinsho Ketsueki; 1995 Jul; 36(7):682-6. PubMed ID: 7563597
[TBL] [Abstract][Full Text] [Related]
24. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
Zangari M; Esseltine D; Lee CK; Barlogie B; Elice F; Burns MJ; Kang SH; Yaccoby S; Najarian K; Richardson P; Sonneveld P; Tricot G
Br J Haematol; 2005 Oct; 131(1):71-3. PubMed ID: 16173965
[TBL] [Abstract][Full Text] [Related]
25. [Clinical trial of a combination of human lymphoblastoid interferon (HLBI), melphalan and prednisolone (HLBI-MP) in multiple myeloma].
Hara M; Nakamura T; Fujii Y
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1338-41. PubMed ID: 3579331
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Cakana A; van de Velde H; Richardson PG;
N Engl J Med; 2008 Aug; 359(9):906-17. PubMed ID: 18753647
[TBL] [Abstract][Full Text] [Related]
27. [A fatal case of aggressive-phase multiple myeloma with ileus and invasion into extramedullary organs].
Takaya N; Miyakoshi S; Kubo K; Mutou Y; Endou Y
Rinsho Ketsueki; 1998 May; 39(5):379-85. PubMed ID: 9637889
[TBL] [Abstract][Full Text] [Related]
28. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
29. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
30. Frontline treatment of multiple myeloma in elderly patients.
Moreau P; Hulin C; Facon T
Blood Rev; 2008 Nov; 22(6):303-9. PubMed ID: 18550234
[TBL] [Abstract][Full Text] [Related]
31. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P
Oncology; 2006; 70(6):474-82. PubMed ID: 17283449
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous involvement in multiple myeloma and bortezomib.
Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
[No Abstract] [Full Text] [Related]
33. [Multiple myeloma with antinuclear antibodies. Its course during cytostatic therapy].
Buttgereit F; Hiepe F; Apostoloff E
Dtsch Med Wochenschr; 1992 May; 117(21):819-22. PubMed ID: 1587216
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma.
Gozzetti A; Defina M; Bocchia M; Fabbri A; Marchini E; Chitarrelli I; Lauria F
Leuk Res; 2010 Nov; 34(11):e288-9. PubMed ID: 20557933
[No Abstract] [Full Text] [Related]
36. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
37. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
[TBL] [Abstract][Full Text] [Related]
38. Update on recent developments for patients with newly diagnosed multiple myeloma.
Palumbo A; Magarotto V; Gay F; Falco P; Bringhen S; Boccadoro M
Ann N Y Acad Sci; 2008 Sep; 1138():19-21. PubMed ID: 18837878
[TBL] [Abstract][Full Text] [Related]
39. Bortezomib plus melphalan and prednisone for multiple myeloma.
Tsubokura M; Kami M; Komatsu T
N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090031
[No Abstract] [Full Text] [Related]
40. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
Palumbo A; Bringhen S; Rossi D; Cavalli M; Larocca A; Ria R; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Morabito F; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Ciccone G; Boccadoro M
J Clin Oncol; 2010 Dec; 28(34):5101-9. PubMed ID: 20940200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
